⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
globenewswire.com
RVMD
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
globenewswire.com
RVMD
Form 8-K
sec.gov
RPRX
RVMD
Form 8-K
sec.gov
RVMDW
RVMD
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
accessnewswire.com
ACTU
RVMD
ERAS
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
globenewswire.com
RVMD
Form 8-K
sec.gov
RVMDW
RVMD
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
globenewswire.com
RVMD